NanoCytology to mitigate overdiagnosis of prostate cancer

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R44CA192701-02
Agency Tracking Number: R44CA192701
Amount: $1,495,536.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: 102
Solicitation Number: PA14-071
Timeline
Solicitation Year: 2014
Award Year: 2016
Award Start Date (Proposal Award Date): 2015-12-16
Award End Date (Contract End Date): 2018-11-30
Small Business Information
1801 MAPLE AVE STE 4316, Evanston, IL, 60201-3149
DUNS: 967856589
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 HARIHARAN SUBRAMANIAN
 (847) 467-3216
 hariharan@nano-cytomics.com
Business Contact
 BETH PARKER
Phone: (860) 545-1508
Email: betheparker@att.net
Research Institution
N/A
Abstract
DESCRIPTION provided by applicant Prostate cancer is the leading cancer among U S men The biggest limitation of current prostate cancer management is that currently it is essentially impossible to accurately prognosticate which patients harbor aggressive cancers that progress into a metastatic disease and need treatment and which patients have non aggressive indolent cancers that would not pose harm Currently available techniques to progrnosticate prostate cancer suffer from lack of clinical utility high cost and or lack of sensitivity We propse a new paradigm to accurately identify patients harboring aggressive versus non aggressive disease among men with prostate cancer managed with active surveillance repeat biopsies every years We propose to achieve this by detecting prostate field carcinogenesis which is the notion that the genetic or environmental milieu that results in carcinogenesis impacts upon the entire prostate Hence not only tumor cells but also a much larger population of cells throughout the prostate which otherwise would appear normal on a biopsy bear the fingerprint of the risk of aggressive cancer Some of the first alterations that develop in cells in field carcinogenesis are at the nanoscale level and are too small to be detected by conventional microscopy as with a pathologist examining prostate biopsies We have developed a new optical technology Partial Wave Spectroscopic PWS microscopy or simply nanocytology which is uniquely suited to detect these subtle alterations in field carcinogenesis We have validated nanocytology in prior clinical trials in seven types of cancer lung colon prostate ovarian esophageal pancreatic and thyroid in patients In a recent study of prostate cancer patients with Gleason disease undergoing Active Surveillance n we found that PWS nanocytology performed on histologically normal prostate epithelium was able to successfully predict subsequent progressors versus non progressors In the future we envision that nanocytology can be coupled into existing prostate cancer care The patients with prostate cancer who already undergo active surveillance will have their biopsies examined via PWS nanocytology which will identify patients with aggressive versus non aggressive tumors In order to achieve this goal as part of this SBIR Fast track application NanoCytomics will first develop a fully automated whole slide fast PWS nanocytology system that is specifically optimized to acquire data on prostate cancer histological sections Phase I In Phase II NanoCytomics will develop standard operating procedures and will develop improved biomarkers that can more accurately identify clinically significant prostate cancer In Phase II we will also validate the biomarkers on an independent data set by performing PWS on archival index biopsies in men diagnosed with prostate cancer who have had a prostatectomy after to years of clinical follow up after the index biopsy Our goal is that by the time the project is completed the technology will be fully developed clinically tested and ready for FDA trials and clinical use PUBLIC HEALTH RELEVANCE Prostate cancer is the nd leading cause of cancer death in U S men In this SBIR Phase I II Fast track application Nanocytomics proposes to develop a new paradigm that can prospectively distinguish patients with indolent prostate cancer from aggressive prostate cancer using an approach that can be couple with the existing active surveillance protocols with no additional procedures

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government